Comparison
21q22 11q22 12 Microdeletion Syndrome C5192593 vs 10q22 3q23 3 Microduplication Syndrome C5190512
Clinical comparison between 21q22 11q22 12 Microdeletion Syndrome and 10q22 3q23 3 Microduplication Syndrome for differential diagnosis and treatment planning.
21q22 11q22 12 Microdeletion Syndrome C5192593
A rare genetic condition involving deletion of a specific region on chromosome 21. It may cause developmental delay, intellectual disability, and distinctive facial features. Management focuses on developmental support and medical monitoring.
10q22 3q23 3 Microduplication Syndrome C5190512
A rare genetic condition where a small amount of chromosomal material is duplicated, causing varied developmental differences. Requires comprehensive medical evaluation.
6 comparison axes
Onset
21q22 11q22 12 Microdeletion Syndrome C5192593
0-0
10q22 3q23 3 Microduplication Syndrome C5190512
0-null
Onset patterns differ
Severity
21q22 11q22 12 Microdeletion Syndrome C5192593
severe
10q22 3q23 3 Microduplication Syndrome C5190512
moderate
Different severity levels
Chronic
21q22 11q22 12 Microdeletion Syndrome C5192593
Chronic
10q22 3q23 3 Microduplication Syndrome C5190512
Chronic
Differing course
Communicable
21q22 11q22 12 Microdeletion Syndrome C5192593
No
10q22 3q23 3 Microduplication Syndrome C5190512
No
Different transmission
Body System
21q22 11q22 12 Microdeletion Syndrome C5192593
congenital
10q22 3q23 3 Microduplication Syndrome C5190512
congenital
Same/different system
Category
21q22 11q22 12 Microdeletion Syndrome C5192593
rare-disease
10q22 3q23 3 Microduplication Syndrome C5190512
genetic
Different category
Bottom line
21q22-11q22-12-microdeletion-syndrome-C5192593 and 10q22-3q23-3-microduplication-syndrome-C5190512 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 21q22 11q22 12 Microdeletion Syndrome C5192593 | 10q22 3q23 3 Microduplication Syndrome C5190512 | Discriminating power |
|---|---|---|---|
| Developmental delay | Described as a possible feature of this deletion. | Varied developmental differences are described; specific pattern is not established. | Low |
| Intellectual disability | Listed as a possible feature. | Not specifically established by the supplied description. | Moderate |
| Distinctive facial features | Described as possible. | Not established in the supplied source. | Moderate |
When to favor each condition
Choose 21q22 11q22 12 Microdeletion Syndrome C5192593 when
Confirmed loss at 21q22.11-q22.12
The diagnosis depends on the chromosomal locus and deletion, not symptoms alone.
High
Developmental delay with intellectual disability and facial differences
These features fit the supplied description but still require genetic confirmation.
Moderate
Need for developmental support and monitoring
Source management emphasizes support rather than a specific drug regimen.
Moderate
Choose 10q22 3q23 3 Microduplication Syndrome C5190512 when
Confirmed gain at 10q22.3-q23.3
A duplication at this locus distinguishes it from a chromosome 21 deletion.
High
Broad or variable developmental differences
The supplied description emphasizes variability and comprehensive evaluation.
Moderate
Uncertain phenotype without locus confirmation
Do not assign either condition until copy-number testing is interpreted clinically.
High
How key tests differ
| Test | 21q22 11q22 12 Microdeletion Syndrome C5192593 | 10q22 3q23 3 Microduplication Syndrome C5190512 | Interpretation |
|---|---|---|---|
| Chromosomal microarray | Copy-number loss involving 21q22.11-q22.12. | Copy-number gain involving 10q22.3-q23.3. | Locus and loss versus gain are the primary distinction; clinician review is required. |
| Karyotype | May miss a small deletion. | May miss a small duplication. | A normal karyotype does not exclude either micro-copy-number condition. |
| Targeted confirmation such as FISH or MLPA | Can support a suspected deletion when appropriately targeted. | Can support a suspected duplication when appropriately targeted. | The assay must target the relevant region; exact method is individualized. |
Prognosis comparison
21q22 11q22 12 Microdeletion Syndrome C5192593
- Outcome
- Long-term outcome is not established; described severity is severe.
- Factors
- Developmental needs, associated findings, and available support may influence course.
10q22 3q23 3 Microduplication Syndrome C5190512
- Outcome
- Long-term outcome is not established; described severity is moderate with variable features.
- Factors
- The extent of developmental differences and associated findings are not fully defined here.
Time frame: Both are described as chronic congenital conditions; onset details for the right are incomplete.
Prognosis should be individualized. No mortality or prevalence comparison is established.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurodevelopmental needs | Delay and intellectual disability are described. Developmental differences may vary; specifics are not established. No comparative complication rates are supplied. |
| Congenital anomalies | Distinctive facial features are described; other anomalies are not specified. Associated anomalies are not established here. Individual evaluation is needed rather than assuming a fixed pattern. |
| Medical complexity | Source severity is severe and monitoring is advised. Source severity is moderate, but evaluation should still be comprehensive. Severity labels do not predict an individual outcome. |
Patient education highlights
- HighGenetic confirmation
Symptoms overlap many conditions; the chromosomal result and clinical interpretation determine the diagnosis.
- HighSupportive care
Care generally centers on developmental support and monitoring. No dose or specific treatment is established here.
- MediumFamily implications
Inheritance and recurrence risk require genetics counseling and cannot be inferred from these summaries.